Yanggu, South Korea
Yanggu, South Korea

Time filter

Source Type

Provided are a PNA probe for detecting nucleotide polymorphism of a target gene, a melting curve analysis method for detecting the nucleotide polymorphism of the target gene using the same, a nucleotide polymorphism analysis method of a target gene including the melting curve analysis method, and a kit for detecting the nucleotide polymorphism of the target gene containing the PNA probe. It is characterized that the PNA probe according to the present invention contains negative charge molecules. The modified PNA probe according to the present invention contains the negative charge molecules to have a high recognition ability with respect to a target DNA and a high coupling ability to the target DNA and to be rapidly dissociated by heat, such that the nucleotide polymorphism analysis may be relatively easily performed even in a heterozygous sample showing two melting curve graphs, and two or more adjacent single nucleotide polymorphisms may be simultaneously analyzed.


The present invention relates to an application of a target nucleic acid detection method using a clamping probe and a detection probe. The method of the present invention can effectively detect a small amount of variation or a specific gene sequence contained in a sample by selective amplification and detection of a trace amount of a target gene to be detected while inhibiting amplification of wild-type genes or undesired genes. Also, it is possible to determine a large number of genotypes at the same time through a melting curve analysis. In particular, the method can be used for diagnosis, prognosis and monitoring of the medical condition of a disease, treatment efficacy evaluation, and for aiding nucleic acid and protein delivery studies and so on, through a very small amount of a mutant genotype that is confirmed at a high detection sensitivity. The method of the present invention comprises a step for evaluating the detection of biomarkers such as EGFR, KRAS, NRAS etc. and the presence of mutations of biomarkers using invasive specimens such as tissues as well as non-invasive specimens (blood, urine, sputum, stool, saliva, and cells). The presence of the biomarker and mutations provides a method used for monitoring of the entire cycle of a related disease, disease prognosis and prediction, decision of disease treatment strategy, disease diagnosis/early diagnosis, disease prevention, and development of disease therapeutics.


Provided are a PNA probe for detecting nucleotide polymorphism of a target gene, a melting curve analysis method for detecting the nucleotide polymorphism of the target gene using the same, a nucleotide polymorphism analysis method of a target gene including the melting curve analysis method, and a kit for detecting the nucleotide polymorphism of the target gene containing the PNA probe. It is characterized that the PNA probe according to the present invention contains negative charge molecules. The modified PNA probe according to the present invention contains the negative charge molecules to have a high recognition ability with respect to a target DNA and a high coupling ability to the target DNA and to be rapidly dissociated by heat, such that the nucleotide polymorphism analysis may be relatively easily performed even in a heterozygous sample showing two melting curve graphs, and two or more adjacent single nucleotide polymorphisms may be simultaneously analyzed.


Disclosed is a probe mixture for real-time detection of target nucleic acids comprising at least one detection probe and at least one clamping probe for inhibiting amplification of wild type genes or unwanted genes, a kit using the same and a method for real-time detection of target nucleic acids using the mixture and the kit.


Yin H.,University of Oxford | Yin H.,Tianjin Medical University | Betts C.,University of Oxford | Saleh A.F.,Medical Research Council Laboratory of Molecular Biology | And 6 more authors.
Molecular Therapy | Year: 2010

Antisense oligonucleotides (AOs) have the capacity to alter the processing of pre-mRNA transcripts in order to correct the function of aberrant disease-related genes. Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle degenerative disease that arises from mutations in the DMD gene leading to an absence of dystrophin protein. AOs have been shown to restore the expression of functional dystrophin via splice correction by intramuscular and systemic delivery in animal models of DMD and in DMD patients via intramuscular administration. Major challenges in developing this splice correction therapy are to optimize AO chemistry and to develop more effective systemic AO delivery. Peptide nucleic acid (PNA) AOs are an alternative AO chemistry with favorable in vivo biochemical properties and splice correcting abilities. Here, we show long-term splice correction of the DMD gene in mdx mice following intramuscular PNA delivery and effective splice correction in aged mdx mice. Further, we report detailed optimization of systemic PNA delivery dose regimens and PNA AO lengths to yield splice correction, with 25-mer PNA AOs providing the greatest splice correcting efficacy, restoring dystrophin protein in multiple peripheral muscle groups. PNA AOs therefore provide an attractive candidate AO chemistry for DMD exon skipping therapy. © The American Society of Gene and Cell Therapy.


Jang H.,Panagene Inc. | Kim J.,Panagene Inc. | Choi J.-J.,Panagene Inc. | Son Y.,Panagene Inc. | Park H.,Panagene Inc.
Journal of Clinical Microbiology | Year: 2010

The detection of antiviral-resistant hepatitis B virus (HBV) mutations is important for monitoring the response to treatment and for effective treatment decisions. We have developed an array using peptide nucleic acid (PNA) probes to detect point mutations in HBV associated with antiviral resistance. PNA probes were designed to detect mutations associated with resistance to lamivudine, adefovir, and entecavir. The PNA array assay was sensitive enough to detect 102 copies/ml. The PNA array assay was able to detect mutants present in more than 5% of the virus population when the total HBV DNA concentration was greater than 104 copies/ml. We analyzed a total of 68 clinical samples by this assay and validated its usefulness by comparing results to those of the sequencing method. The PNA array correctly identified viral mutants and has high concordance (98.3%) with direct sequencing in detecting antiviral-resistant mutations. Our results showed that the PNA array is a rapid, sensitive, and easily applicable assay for the detection of antiviral-resistant mutation in HBV. Thus, the PNA array is a useful and powerful diagnostic tool for the detection of point mutations or polymorphisms. Copyright © 2010, American Society for Microbiology. All Rights Reserved.


Oh S.Y.,Panagene Inc. | Ju Y.,Panagene Inc. | Kim S.,Panagene Inc. | Park H.,Panagene Inc.
Oligonucleotides | Year: 2010

MicroRNAs (miRNAs) are noncoding RNAs approximately 22 nucleotides in length that play a major role in the regulation of important biological processes, including cellular development, differentiation, and apoptosis. Antisense oligonucleotides against miRNAs are useful tools for studying the biological mechanisms and therapeutic targets of miRNAs. Various antisense oligonucleotides chemistries, including peptide nucleic acids (PNAs), have been developed to enhance nuclease-resistance and affinity and specificity for miRNA targets. PNAs have a greater specificity and affinity for DNA and RNA than do natural nucleic acids, and they are resistant to nucleases-an essential property of an miRNA inhibitor that will be exposed to cellular nucleases. However, the main limiting factor in the use of PNAs is their reduced penetration into cells. Recently, several cell-penetrating peptides (CPPs) have been investigated as a means to overcome the limited penetration of PNAs. Here, we evaluated the ability of 11 CPPs to transport PNAs inside cells in the absence of transfection reagents and then investigated the ability of these CPPs to inhibit miRNAs. Of the 11 CPPs tested, Tat-modified-conjugated PNA showed the most effective penetration into cells in the absence of transfection reagents and most effectively inhibited miRNAs. Our data demonstrate that Tat-modified-conjugated CPP is the most suitable for supporting PNA-mediated miRNA inhibition. © 2010, Mary Ann Liebert, Inc.


Patent
Panagene Inc. | Date: 2010-04-14

This application relates to monomers of the general formula (I) for the preparation PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: (I) wherein E is nitrogen or C-R; J is sulfur or oxygen; R, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural a-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.


Disclosed are a microRNA antisense PNA capable of inhibiting the activity or function of microRNA, a composition for inhibiting the activity or function of microRNA containing the same, a method for inhibiting the activity or function of microRNA using the same, and a method for evaluating the effectiveness thereof.


Trademark
Panagene Inc. | Date: 2012-11-27

DNA chips; Optical glass for the manufacture of laboratory equipment; Waling glass in the nature of laboratory glassware; lens glass in the nature of eyeglass lenses; ultraviolet-ray transmitting glass in the nature of laboratory glassware; infrared-ray absorbing glass in the nature of laboratory glassware; glass covered with an electrical conductor for use in the manufacture of laboratory glassware; apparatus and instruments for physics, namely, polymerase chain reaction machine, image scanner, spectrophotometer, electrophoresis apparatus for use in laboratories, hybridization chamber, and microarray of biological probes; chemistry apparatus and instruments, namely, pH meter and chromatography apparatus for use in polymer synthesis and purification; and diffraction apparatus, namely, optical lenses and prisms for microscopes. Vaccines and pharmaceutical research and development; Research of geriatric diseases; Bacteriological research; Cancer research; Pharmaceutical development; pharmaceutical research; pharmaceutical testing in the field of pharmacology; chemical-pharmaceutical testing; Medical research, namely, research of medicine, research and development of DNA chips, research of biotechnology; scientific and technical consultation in the field of biotechnology; biological research; Chemical, biochemical, biological and bacteriological research and analysis, namely, analysis of biochemistry, analysis of DNA, and research of genetics; Laboratory apparatus rental; Research and development for others in the fields of microarray; rental of research installations in the nature of laboratory apparatus and instruments; chemistry services, namely, chemical analysis.

Loading Panagene Inc. collaborators
Loading Panagene Inc. collaborators